Healthcare & Life Sciences
Cellaïon
Belgium
series-b
series-b
Stage
1
Investors
About
Cellaïon is a Walloon biotechnology company developing cell therapies for severe liver diseases, with its lead product HepaStem® in advanced clinical development for Acute-on-Chronic Liver Failure (ACLF) and a pipeline targeting acute toxic hepatitis, acute decompensation, and NASH.
Explore Cellaïon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.